XML 137 R93.htm IDEA: XBRL DOCUMENT
v3.22.4

Principal alliances -Collaboration agreements on human therapeutic antibodies (Details) € in Millions, $ in Millions |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Apr. 01, 2020 | Jul. 01, 2015 agreement | Nov. 30, 2007 agreement | Mar. 31, 2022 | Dec. 31, 2022 Rate | Dec. 31, 2022 EUR (€) bond Rate | Dec. 31, 2022 USD ($) bond Rate | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2015
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales | € |  |  |  |  |  | € 42,997 |  | € 37,761 | € 36,041 | [1] |
US |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales | € |  |  |  |  |  | € 18,275 |  | € 14,385 | € 13,465 |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of agreements signed | agreement |  |  | 2 |  |  |  |  |  |  |  |
Phase III costs, responsibility percentage |  |  |  |  |  | 80.00% | 80.00% |  |  |  |
Phase III costs, responsibility percentage for Regeneron |  |  |  |  |  | 20.00% | 20.00% |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) |  |  |  | 10.00% | 20.00% |  |  |  |  |  |
Percentage of cumulative development costs reimbursed |  |  |  |  |  | 50.00% | 50.00% |  |  |  |
Period before scheduled launch date |  |  |  |  |  | 24 months | 24 months |  |  |  |
Number of payments | bond |  |  |  |  |  | 2 | 2 |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales of antibodies, first achievement |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment related to attainment of goal |  |  |  |  |  |  | $ 50 |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales of antibodies, first achievement | Antibodies |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  | 2,000 |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales of antibodies, second achievement |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment related to attainment of goal |  |  |  |  |  |  | 50 |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales of antibodies, second achievement | Antibodies |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  | $ 2,500 |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Prior agreement |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate |  |  |  |  | 10.00% | 10.00% | 10.00% |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | New agreement |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate |  |  |  |  |  | 20.00% | 20.00% |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales Of Antibodies, Third Achievement |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payment related to attainment of goal |  |  |  |  |  |  | $ 50 |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales Of Antibodies, Third Achievement | Antibodies |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Net sales |  |  |  |  |  |  | $ 3,000 |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | US |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of profits and losses arising from commercial operations |  |  |  |  |  | 50.00% | 50.00% |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Outside the United States |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of losses arising from commercial operations |  |  |  |  |  | 55.00% | 55.00% |  |  |  |
Royalty expense, percentage (percentage) | 5.00% |  |  |  |  |  |  |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Outside the United States | Bottom of range |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations |  |  |  |  |  | 55.00% | 55.00% |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Outside the United States | Top of range |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations |  |  |  |  |  | 65.00% | 65.00% |  |  |  |
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about Principal Alliances [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of agreements signed | agreement |  | 2 |  |  |  |  |  |  |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) |  |  |  |  |  |  |  |  |  |  | 10.00%
Percentage of cumulative development costs reimbursed |  |  |  |  |  |  |  |  |  |  | 50.00%
[1] | Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disclosure of detailed information about Principal Alliances [Line Items] + References No definition available. + Details
Name: | sny_DisclosureOfDetailedInformationAboutPrincipalAlliancesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Agreements Signed + References No definition available. + Details
Name: | sny_NumberOfAgreementsSigned
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Payments + References No definition available. + Details
Name: | sny_NumberOfPayments
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment Related To Attainment Of Goal + References No definition available. + Details
Name: | sny_PaymentRelatedToAttainmentOfGoal
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of cumulative development costs reimbursed. + References No definition available. + Details
Name: | sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Losses Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfLossesArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of profit share on counter parties profit. + References No definition available. + Details
Name: | sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of profits and losses arising from commercial operations. + References No definition available. + Details
Name: | sny_PercentageOfProfitsAndLossesArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Profits Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfProfitsArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Second Part Of Development Costs Funded + References No definition available. + Details
Name: | sny_PercentageOfSecondPartOfDevelopmentCostsFunded
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of second part of development costs funded by other party. + References No definition available. + Details
Name: | sny_PercentageOfSecondPartOfDevelopmentCostsFundedByOtherParty
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period Before Launch Date During Which Commercial Expenses Of Antibodies Co-Developed Under License Agreement Are Shared + References No definition available. + Details
Name: | sny_PeriodBeforeLaunchDateDuringWhichCommercialExpensesOfAntibodiesCoDevelopedUnderLicenseAgreementAreShared
Namespace Prefix: | sny_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Expense, Percentage + References No definition available. + Details
Name: | sny_RoyaltyExpensePercentage
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesFirstAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_AntibodiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesSecondAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_PriorAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_NewAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_TypesOfAgreementAxis=sny_SalesOfAntibodiesThirdAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OutsideUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |